Samsung BioLogics says 180,000L plant is completed but not validated
The Korean CDMO says construction of its third – and largest – biomanufacturing facility is complete with the validation process expected to take a year.
Archives for December 1, 2017
Mylan: Reinspection of Biocon plant brings biosimilar confidence
The EMA has accepted to review Mylan’s trastuzumab and pegfilgrastim biosimilars amid remediation efforts at biomanufacturing partner Biocon’s fill and finish plant in India.
Orchard expands Californian in-house gene therapy capabilities
Orchard Therapeutics has opened a second facility in California to support the manufacture of its ex-vivo lentiviral gene therapy products.